Ignalis 100 Tablet contains Sitagliptin 100 mg, a potent dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for the management of type 2 diabetes mellitus. Sitagliptin enhances the body's ability to regulate blood glucose by increasing the levels of incretin hormones, which stimulate insulin release from pancreatic beta cells and suppress glucagon secretion from alpha cells in a glucose-dependent manner. This dual action helps improve glycemic control without causing significant hypoglycemia. Ignalis 100 is typically prescribed as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, either as monotherapy or in combination with other antidiabetic agents such as metformin, sulfonylureas, or insulin. The medication is administered orally once daily, with or without food. Clinical studies have demonstrated that Sitagliptin effectively lowers HbA1c levels and fasting plasma glucose, contributing to improved long-term glycemic management. Common adverse effects may include nasopharyngitis, headache, and upper respiratory tract infections, while serious side effects are rare but may include pancreatitis and hypersensitivity reactions. Regular monitoring of renal function is recommended, as dose adjustments may be necessary in patients with renal impairment. Ignalis 100 should be used under medical supervision to optimize diabetes management and minimize complications.